Zacks Investment Research downgraded shares of OPHTHOTECH CORP (OPHT) from OUTPERFORM to NEUTRAL on February 27, 2015, with a target price of $60.00.
Ophthotech Corporation is a biopharmaceutical company. It is focused on developing and commercializing novel therapies for the treatment of diseases of the eye. The Company is developing Fovista and ARC1905, which are under clinical trials, for the treatment of wet AMD. Ophthotech Corporation is headquartered in New York.
To get a free copy of the research report on OPHTHOTECH CORP (OPHT),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment